EA201992885A1 - Антитела, специфически связывающиеся с pd-1, и способы их применения - Google Patents
Антитела, специфически связывающиеся с pd-1, и способы их примененияInfo
- Publication number
- EA201992885A1 EA201992885A1 EA201992885A EA201992885A EA201992885A1 EA 201992885 A1 EA201992885 A1 EA 201992885A1 EA 201992885 A EA201992885 A EA 201992885A EA 201992885 A EA201992885 A EA 201992885A EA 201992885 A1 EA201992885 A1 EA 201992885A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ways
- application
- specifically binding
- antibodies specifically
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Антитела, которые специфически связываются с PD-1, или их антигенсвязывающие фрагменты, полинуклеотиды, кодирующие антитела или фрагменты, а также способы получения и применения вышеуказанного можно использовать для лечения воспалительных или иммунных расстройств.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862673185P | 2018-05-18 | 2018-05-18 | |
PCT/US2018/035843 WO2018226580A2 (en) | 2017-06-05 | 2018-06-04 | Antibodies that specifically bind pd-1 and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992885A1 true EA201992885A1 (ru) | 2020-05-15 |
Family
ID=70847679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992885A EA201992885A1 (ru) | 2018-05-18 | 2018-06-04 | Антитела, специфически связывающиеся с pd-1, и способы их применения |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201992885A1 (ru) |
-
2018
- 2018-06-04 EA EA201992885A patent/EA201992885A1/ru unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202092847A1 (ru) | Антитела к cd3 и их применение | |
EA201891093A1 (ru) | Антитела, специфически связывающие pd-1, и их применение | |
EA201990243A1 (ru) | Новые антитела, которые специфически связываются с эпитопами вируса зика, и их применения | |
EA201890453A1 (ru) | Анти-angptl8 антитела и их применение | |
MY191649A (en) | Antibodies to tigit | |
EA202092839A1 (ru) | Агенты, связывающиеся с psma, и виды их применения | |
PH12019502755A1 (en) | Antibodies that specifically bind pd-1 and methods of use | |
EA201990594A1 (ru) | Анти-tim-3 антитела и их применение | |
EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
EA202092605A1 (ru) | Антитела к ил-11ra | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201792467A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
EA201890834A1 (ru) | Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения | |
EA201591716A1 (ru) | Антитела анти-il-33 и их применение | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
EA201691556A1 (ru) | Молекулы антител к tim-3 и их применение | |
EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
EA201890143A3 (ru) | Антитела против pdgfr-бета и их применения | |
EA202192736A1 (ru) | Антитела, содержащие только тяжелые цепи, которые связываются с псма | |
EA201491214A1 (ru) | Композиции и способы применения антител, нацеленных на фактор p | |
PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
EA201591791A1 (ru) | Антитела pac1 человека | |
EA201290589A1 (ru) | Cd127-связывающие белки | |
EA201890928A1 (ru) | Антигенсвязывающие белки, которые активируют лептиновый рецептор | |
EA201592285A1 (ru) | Антигенсвязывающие белки к рецептору онкостатина м |